Charles River Laboratories and Pfizer have entered into a marketing and distribution agreement to provide certain Pfizer-developed genetically modified research models to the biomedical research community. Charles River will supply pre-competitive, transgenic research models developed by Pfizer covering a range of therapeutic areas, including neuroscience, diabetes and cardiovascular disease.

“Charles River is extremely pleased to partner with Pfizer to further expand our growing portfolio of genetically modified research models that we can make available to our global client base,” said Dr. Iva Morse, corporate vice president, Global Research Model Services at Charles River. “The use of genetically modified research models continues to emerge as an important tool to allow scientists in their research to target specific disease states and genetic markers. We appreciate that Pfizer has selected Charles River to bring their unique models to market.”

Rick Connell, vice president and worldwide head of External Research Solutions Center of Excellence at Pfizer, added, “This agreement with Charles River aligns with Pfizer’s strategy to externalize our pre-competitive tools and assets to a broader community of scientists outside of Pfizer’s walls. We collectively share an interest in seeing science advance to enable the continued development of innovative medicines for patients. Charles River is a leader in providing products and services to the biomedical research community, so we expect that our genetically modified models will be delivered to their clients with the highest standards of quality and care for which they are globally recognized.”